NOW Is the Time for Hepatitis C Virus Elimination
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.
Communities as Actors in the Research and Development Process
This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.
A Community Update on AbbVie’s HIV Cure Research Program
This webinar was held on December 5, 2023, and provided an update on HIV cure-related research studies being conducted by the company AbbVie; the recording of the webinar is now online.
Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.
2023 Report on TB Research Funding Trends
Tuberculosis Research Funding Trends 2005 – 2022, the 18th annual installment of our series assessing the state of TB R&D, is based on surveys of biomedical research funders conducted by TAG with support from Stop TB Partnership.
Submission on the Right to Access and Take Part in Scientific Progress
TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the new DR-TB treatment regimens, including an overview of findings from…
Story: CRISPR-Based Cure for HIV “could be months away”
October/November 2023 Media coverage: CRISPR gene therapy appears safe, but claims of an imminent HIV cure are premature - Liz Highleyman, AIDSMap, November 3, 2023 Cure for HIV could be months away as first three patients are injected with new…
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.